FDA lifts pause on Valneva's chikungunya vaccine in elderly
Source: SeekingAlpha
2025-08-07 09:45:04 ET
More on Valneva
- Valneva SE (VALN) Q1 2025 Earnings Call Transcript
- CDC mulls travel notice for China amid rise in chikungunya cases
- Valneva's chikungunya vaccine suspension gets lifted for older adults
- Seeking Alpha’s Quant Rating on Valneva
- Historical earnings data for Valneva
Read the full article on Seeking Alpha
For further details see:
FDA lifts pause on Valneva's chikungunya vaccine in elderly
Valneva SE
NASDAQ: VALN
VALN Trading
-0.99% G/L:
$6.50 Last:
583,920 Volume:
$6.56 Open:
VALN Latest News
March 18, 2026 08:00:00 am
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
VALN Stock Data
$798,793,290
73,508,485
N/A
10
N/A
Biotechnology & Life Sciences
Healthcare
FR
Lyon
